|
24 Jun 2018 |
Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
|
|
22 Jun 2018 |
Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia
|
|
21 Jun 2018 |
Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials
|
|
19 Jun 2018 |
Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery
|
|
19 Jun 2018 |
Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
|
|
19 Jun 2018 |
Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
|
|
19 Jun 2018 |
Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B
|
|
19 Jun 2018 |
Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress
|
|
15 Jun 2018 |
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
|
|
15 Jun 2018 |
Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
|
|
14 Jun 2018 |
BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
|
|
14 Jun 2018 |
ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States
|
|
11 Jun 2018 |
FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label
|
|
11 Jun 2018 |
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity
|
|
11 Jun 2018 |
AOP Orphan Announces Progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
|
|
08 Jun 2018 |
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
|
|
06 Jun 2018 |
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome
|
|
05 Jun 2018 |
U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
|
|
04 Jun 2018 |
Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting
|
|
03 Jun 2018 |
Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 Plus FOLFOX in Hepatocellular Carcinoma
|
|
01 Jun 2018 |
MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
|
|
31 May 2018 |
Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI-PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma
|
|
31 May 2018 |
Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial
|
|
29 May 2018 |
Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)
|
|
28 May 2018 |
Octapharma Share Promising Preclinical Data for SubQ-8, a Novel Subcutaneous Recombinant FVIII, at WFH 2018
|
